Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Ferrante

Showing results (311-320 of 319) with videos related to

Pageof 32
Sort By:
You have reached the last page of results.This site can display upto 319 results.
Lancet (London, England)|June 1, 2022
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trialsGeert D'Haens, Remo Panaccione, Filip Baert, et al.
Lancet (London, England)|June 1, 2022
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trialMarc Ferrante, Remo Panaccione, Filip Baert, et al.
Autoimmunity Reviews|July 15, 2020
2020 international consensus on ANCA testing beyond systemic vasculitisSergey Moiseev, Jan Willem Cohen Tervaert, Yoshihiro Arimura, et al.
Gastroenterology|March 18, 2026
Identification of a druggable target that predicts postoperative Crohn's disease recurrenceSare Verstockt, Julian Schwärzler, Peter Willeit, et al.
Journal of Crohn'S & Colitis|November 29, 2023
A Core Outcome Set for Inflammatory Bowel Diseases: Development and Recommendations for Implementation in Clinical Practice Through an International Multi-stakeholder Consensus ProcessLiselotte Fierens, Nicholas Carney, Gottfried Novacek, et al.
Inflammatory Bowel Diseases|May 23, 2018
Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European StudyUri Kopylov, Bram Verstockt, Luc Biedermann, et al.
Inflammatory Bowel Diseases|June 8, 2017
Impact of Infliximab and Cyclosporine on the Risk of Colectomy in Hospitalized Patients with Ulcerative Colitis Complicated by Cytomegalovirus-A Multicenter Retrospective StudyUri Kopylov, Konstantinos Papamichael, Konstantinos Katsanos, et al.
Gastroenterology|April 1, 2020
Deep Remission at 1 Year Prevents Progression of Early Crohn's DiseaseRyan C Ungaro, Clara Yzet, Peter Bossuyt, et al.
United European Gastroenterology Journal|July 11, 2025
Assessment of PredictSURE IBD Assay in a Multinational Cohort of Patients With Inflammatory Bowel DiseaseDahham Alsoud, Nurulamin M Noor, Lea Ann Chen, et al.
Pageof 32

Showing results (311-320 of 319) with videos related to

Sort By:
Pageof 32
You have reached the last page of results.This site can display upto 319 results.
Lancet (London, England)|June 1, 2022
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trialsGeert D'Haens, Remo Panaccione, Filip Baert, et al.
Lancet (London, England)|June 1, 2022
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trialMarc Ferrante, Remo Panaccione, Filip Baert, et al.
Autoimmunity Reviews|July 15, 2020
2020 international consensus on ANCA testing beyond systemic vasculitisSergey Moiseev, Jan Willem Cohen Tervaert, Yoshihiro Arimura, et al.
Gastroenterology|March 18, 2026
Identification of a druggable target that predicts postoperative Crohn's disease recurrenceSare Verstockt, Julian Schwärzler, Peter Willeit, et al.
Journal of Crohn'S & Colitis|November 29, 2023
A Core Outcome Set for Inflammatory Bowel Diseases: Development and Recommendations for Implementation in Clinical Practice Through an International Multi-stakeholder Consensus ProcessLiselotte Fierens, Nicholas Carney, Gottfried Novacek, et al.
Inflammatory Bowel Diseases|May 23, 2018
Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European StudyUri Kopylov, Bram Verstockt, Luc Biedermann, et al.
Inflammatory Bowel Diseases|June 8, 2017
Impact of Infliximab and Cyclosporine on the Risk of Colectomy in Hospitalized Patients with Ulcerative Colitis Complicated by Cytomegalovirus-A Multicenter Retrospective StudyUri Kopylov, Konstantinos Papamichael, Konstantinos Katsanos, et al.
Gastroenterology|April 1, 2020
Deep Remission at 1 Year Prevents Progression of Early Crohn's DiseaseRyan C Ungaro, Clara Yzet, Peter Bossuyt, et al.
United European Gastroenterology Journal|July 11, 2025
Assessment of PredictSURE IBD Assay in a Multinational Cohort of Patients With Inflammatory Bowel DiseaseDahham Alsoud, Nurulamin M Noor, Lea Ann Chen, et al.
Pageof 32